BMS 599626 dihydrochloride
Cat. No. 5022
Chemical Name: (3S)-3-Morpholinylmethyl-[4-[[1-[(3
Biological ActivityPotent and selective EGFR and ErbB2 inhibitor (IC50 values are 22 nM and 32 nM respectively). Also inhibits HER4 (IC50 = 190 nM). Inhibits EGFR and ErbB2 with 100-fold greater potency than MEK and Lck. Antiproliferative agent in vitro and anti-tumorigenic agent in vivo. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Gavai et al (2009) Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J.Med.Chem. 52 6527. PMID: 19821562.
Wong et al (2006) Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin.Cancer Res. 12 6186. PMID: 17062696.
If you know of a relevant reference for BMS 599626 dihydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BMS 599626 dihydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BMS 599626 dihydrochloride, supplier, BMS599626, potent, selective, HER1, HER2, EGFR, erbB-2, erbB2, tyrosine, kinase, inhibitors, inhibits, kinases, receptors, growth, factor, Neu, antitumor, antitumour, antiproliferative, Tocris Bioscience, EGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXLPF 06273340
Potent and selective pan-Trk inhibitor; peripherally restricted
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.